{'fraction_non_alphanumeric': 0.036245833137706, 'fraction_numerical': 0.029250199539884503, 'mean_word_length': 5.528582375478927, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
An Integrated View of Deubiquitinating Enzymes Involved in Type I Interferon Signaling, Host Defense and Antiviral Activities

Viral infectious diseases pose a great challenge to human health around the world. Type I interferons (IFN-Is) function as the first line of host defense and thus play critical roles during virus infection by mediating the transcriptional induction of hundreds of genes. Nevertheless, overactive cytokine immune responses also cause autoimmune diseases, and thus, tight regulation of the innate immune response is needed to achieve viral clearance without causing excessive immune responses. Emerging studies have recently uncovered that the ubiquitin system, particularly deubiquitinating enzymes (DUBs), plays a critical role in regulating innate immune responses. In this review, we highlight recent advances on the diverse mechanisms of human DUBs implicated in IFN-I signaling. These DUBs function dynamically to calibrate host defenses against various virus infections by targeting hub proteins in the IFN-I signaling transduction pathway. We also present a future perspective on the roles of DUB-substrate interaction networks in innate antiviral activities, discuss the promises and challenges of DUB-based drug development, and identify the open questions that remain to be clarified. Our review provides a comprehensive description of DUBs, particularly their differential mechanisms that have evolved in the host to regulate IFN-I-signaling-mediated antiviral responses.


INTRODUCTION
Pathogen invasions are responsible for many diseases and exert extensive effects on human health ranging from mild to potentially fatal infections. Critically, the prevalence of certain viruses, such as SARS-CoV-2, can even pose a serious threat to global human health (1). The host's immune system evolved as the first line of defense against the invasion of microbial pathogens and can also trigger various immune responses through dynamic interactions with differential cellular components (2,3). Among all the signaling pathways examined, much attention has been given to the signaling events triggered by one class of molecules during the activation of innate immune responses, pattern-recognition receptors (PRRs). Innate immune responses are rapidly initiated when host cellular PRRs, such as Toll-like receptors (TLRs), RIG-I-like receptors (RLRs), NOD-like receptors (NLRs), and DNA sensors encounter pathogen-associated molecular patterns (PAMPs) of fungal, bacterial, or viral origin (4,5). Toll-like receptors, including TLR3, TLR4, TLR7, TLR8, and TLR9 can sense endosomal nucleic acids derived from pathogens and infected apoptotic cells. Specifically, TLR3 and TLR7/8 recognize double-stranded RNA (dsRNA) and singlestranded RNA (ssRNA), respectively, whereas TLR9 detects unmethylated CpG double-stranded DNA species (6). The activation of TLR3, TLR4, TLR7, TLR8, and TLR9 leads to activation of the adapter myeloid differentiation 88 (MyD88)dependent pathway, which causes IRF7 activation through a TRAF6-dependent mechanism (TLR7/8/9) or the Toll/ interleukin-1 (IL-1) receptor-domain-containing adapterinducing IFNb (TRIF)-dependent pathway and thus leads to IRF3 and IRF7 activation through a TBK1-dependent mechanism (TLR3/4) (7)(8)(9). RLRs are another critical sensor of virus infection. These protein family members include retinoic acid-inducible gene I (RIG-I, also known as Ddx58), melanoma differentiation-associated protein 5 (MDA5, also known as Ifih1 or Helicard), and laboratory of genetics and physiology protein 2 (LGP2) (10). Viral 5' ppp RNA, and longer double-stranded (ds) RNA are often recognized by RIG-I and MDA5, respectively, and both proteins share two N-terminal caspase activation and recruitment domains (CARDs), which are needed for interaction with the mitochondrial antiviral signaling protein (MAVS, also termed IPS-1, VISA or CARDIF). The interacting components then activate MAVS and TNF receptor-associated factors (TRAF)-mediated downstream signaling during virus infection (11). Ultimately, the viruses recognized by different host sensors induce antiviral responses by regulating multiple signaling pathways, which are characterized by rapid gene expression of inflammation-inducing molecules and/or cytokines, including interferons (12)(13)(14)(15).
Type I IFNs (also called IFNa/b or IFN-Is), which serve as the first line of host defense against virus infection can be induced in almost all cells in the body. A dysregulated interferon-response is thus associated with many diseases, such as autoimmune diseases (16), infectious diseases (17), and the recent severe coronavirus diseases, which have caused a major ongoing pandemic worldwide (18). The critical cytosolic DNA sensor, cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) synthase (cGAS) often recognizes viral DNA and triggers downstream immune responses through the molecule stimulator of interferon genes (STING, also known as MITA, MPYS, ERIS, or TMEM173) (19). STING further activates TRAFs, which in turn activate TANKbinding kinase 1 (TBK1) or IkB kinase (IKK), and this activation leads to the activation of nuclear factor-kappa enhancer-binding protein (NF-kB) or interferon regulatory factor 3 or 7 (IRF3 or IRF7, respectively). The activated IRF3 and IRF7 complex ultimately translocates the nucleus, which leads to the transcriptional induction of multiple IFNs ( Figure 1A) (20).
Furthermore, the secreted IFN-Is bind to and signal through a heterodimeric transmembrane receptor composed of the subunits IFNAR1 and IFNAR2. The ligation of IFNAR activates the receptor-associated protein tyrosine kinases Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2). In the canonical IFNARmediated downstream signaling pathway, activated JAK1 and TYK2 induce phosphorylation of the signal transducer and activator of transcription 1 (STAT1) and STAT2 molecules present in the cytosol, which leads to the dimerization, nuclear translocation, and binding of these molecules to IRF9 to form the ISG factor 3 (ISGF3) complex. This complex then enters the nucleus and binds to DNA sequences termed interferon-sensitive response elements (ISREs) (with the consensus sequence TTTCNNTTTC), which results in induction of the transcription of several hundred IFN-stimulated genes (ISGs), including Mx1, OAS, STAT1, interferon-regulatory factors (IRFs) and other antiviral genes (21) ( Figure 1B). These ISGs function to induce an antiviral state within the cell. Thus, it can be concluded that host antiviral efficiencies are tightly regulated not only at the virus-induced IFN-I production level but also at the interferon receptor-mediated downstream signaling level.
Currently, post-translational modifications (PTMs), which involve the covalent linkage of new functional groups to amino acid chains, have remarkably expanded the functions of proteins. Over the years, an increasing number of studies have uncovered that PTMs also play pivotal roles during host innate immune responses upon virus infection (22,23). In particular, ubiquitination (also known as ubiquitylation or ubiquitinylation) events in which 8.5-kDa ubiquitin (Ub) is conjugated to one or more lysine residues of proteins are broadly involved in antiviral signaling by regulating the stability, folding, and location of proteins or by interacting with other proteins in the signaling transduction pathway (22,24). In general, ubiquitination involves three sequential steps: an initial activation step catalyzed by the Ub-activating enzyme (E1), an intermediate step in which Ub is covalently linked to a conjugating enzyme (E2), and a final specific step in which Ub reaches its ultimate destination of the substrate amino group through a reaction catalyzed by a ligase enzyme (E3) (25)(26)(27). Substrate-conjugated ubiquitin can be modified by additional Ub molecules to build polyubiquitin chains. The C-terminal carboxyl group of the distal Ub moiety is covalently attached to either the first methionine (M1) of the proximal Ub moiety or one of the seven lysine (K) residues K6, K11, K27, K29, K33, K48, and K63 to result in the formation of linear Ub chains or polyubiquitin chains (28)(29)(30). Homotypic polyubiquitin chains are often referred to as a single type of polyubiquitin linkage, whereas heterotypic polyubiquitin chains are characterized by the presence of at least two different types of linkages within the same polymer (31).
Similar to other PTMs, ubiquitination is reversible, and the reversal process is implemented by an array of proteases termed deubiquitinating enzymes (DUBs) or deubiquitinating peptidases. Approximately 100 DUBs encoded in the human genome. These DUBs have been categorized into at least seven families based on their homology domains and cleavage preferences: namely, ubiquitin-specific proteases (USPs), ubiquitin C-terminal hydrolases (UCHs), ovarian tumour proteases (OTUs), Machado-Joseph disease protease family members (MJDs), the motif interacting with the Ub (MIU)-containing novel DUB family (MINDYs), the JAB1/MPN/MOV34 metalloenzyme family (JAMMs, also termed MPN+), zinc fingers with UFM1-specific peptidase domain proteins (ZUFSPs), and other members identified recently (32)(33)(34)(35)(36) (Figure 2). These DUBs often contain a catalytic domain surrounded by one or more accessory domains, and some of these domains contribute to Ub binding and target recognition (37). One of the best-characterized functions of DUBs is the removal of monoubiquitin and polyubiquitin chains from proteins, thus ensuring that the Ub-proteasome system (UPS) functions properly and recycles free Ub for reuse to maintain the homeostasis of the polyubiquitin pool (38,39). Analogous to the dynamic and crucial roles of ubiquitination events shown previously, DUB-mediated deubiquitination events also play important roles in the antiviral innate immune response (23,24,40,41). Here, we summarize the differential regulatory roles of human DUBs involved in the IFN-I signaling transduction pathway during viral infections. Integrated analyses of DUBs involved in the IFN-I signaling transduction pathway might improve our understanding of their diverse regulatory mechanisms and host antiviral activities, and facilitate the development of therapeutic targets to improve host antiviral efficiency in the future.

DUBS REGULATE VIRUS-INDUCED IFN-I PRODUCTION AND ANTIVIRAL ACTIVITIES
Constitutively expressed RLRs often reside in the cytoplasm of uninfected cells in an auto-repressed, inactive state (42). However, upon viral infection, the master regulators RIG-I and MDA5 are   (50), and c-Cbl (51), regulate RIG-I signaling by modulating Ub chains from various signaling proteins. Among these, the K63-linked ubiquitination of RIG-I often represents a critical step in promoting the activation of IFN-I signaling (45,46,52). Intriguingly, IFN stimulation could also promote an increase in the expression level of RIG-I. Thus, the protein turnover and activity of RIG-I must be tightly regulated to ensure restoration to homeostasis and to avoid hyperactivation of IFN and cytokine signaling. To the best of our knowledge, at least nine DUBs, A20, CYLD, USP3, USP5, USP14, USP15, USP21, USP25, and USP27X, have been proposed to counteract the K63linked ubiquitination of RIG-I and, thereby attenuate downstream signaling and IFN-b production ( Table 1 and Figure 3) (58,76,93). However, unlike the nine above-mentioned Dubs, USP4 and USP17 are the two DUBs that positively regulate virus-induced IFN-I signaling by increasing the stability of RIG-I ( Table 1 and Figure 3). Congruently, the overexpression of USP4 or USP17 significantly promotes virus-induced IFN production and thereby restricts virus replication, whereas the knockdown of USP4 or USP17 has the opposite effect (77,87). Moreover, DUBs also exhibit different functions under different contexts. For example, the deubiquitinating enzyme USP15 negatively regulates virusinduced IFN-I production by targeting RIG-I (84). However, USP15 has also been identified to positively regulate type I IFN responses by decreasing the polyubiquitination level of TRIM25 (85,86). Because the function of DUBs can be altered by various PTMs under differential contexts (123), the discrepancy that USP15 exerts both positive and negative effects may arise from the context-specific PTM of USP15 itself, which may allow dynamic fine-tuning of the signaling. Among the DUBs that interact with STING, five members, namely CYLD, OTUD5, USP18 (also termed UBP43), USP20, and USP44, have been    activation and aggregation, which is promoted by K63-linked ubiquitination catalyzed by TRIM31 (124), are counteracted by OTUD3 (65). In addition, OTUD3-deficient mice also exhibit decreased morbidity after infection with vesicular stomatitis virus (VSV), which might result from increased production of cytokines and decreased viral replication (65). In addition, both OTUD3 and A20 negatively regulate the IFN-mediated antiviral response by modulating the polyubiquitination level of MAVS (125,126). However, OTUD4 positively regulates IFN signaling and enhances host antiviral activities by deubiquitinating K48-Ub on MAVS (66). Among the DUBs that interact with cGAS or MDA5, USP27X (98) and USP29 (99) stabilize cGAS and thus positively regulate IFN production and antiviral activities. The knockout of USP27X in mouse macrophages significantly impairs innate antiviral responses (98), whereas the knockdown or knockout of USP29 severely impairs HSV1-or cytosolic DNA-induced expression of IFN-Is and proinflammatory cytokines (99). In addition, USP17 promotes virus-induced IFN-I production by decreasing the polyubiquitination level of MDA5 (87). Notably, UCHL1, OTUB1, OTUB2, OTUD5, USP25, MYSM1, and MCPIP1 ( Figure 3A) negatively regulate virus-induced IFN-I production and antiviral activities by cleaving K63-linked or other types of polyubiquitin chains from TRAF3 or TRAF6. Regarding the kinase TBK1, a previous study showed that the T cell anergyrelated E3 Ub ligase RNF128 catalyzes the K63-linked polyubiquitination of TBK1, which causes TBK1 and IRF3 activation, and IFN-b production (127). The E3 ligases DTX4, Triad3A, and TRIP have also been identified to conjugate K48linked polyubiquitin chains on TBK1, which results in TBK1 degradation and subsequent inhibition of IFN-Is (128)(129)(130). However, DUBs cleave the polyubiquitin chains of TBK1 to reverse the ubiquitination process mediated by E3 ligases ( Table 1 and Figure 3). For example, CYLD removes polyubiquitin chains from TBK1 and RIG-I and thus inhibits the IRF3 signaling pathway and IFN production triggered by RIG-I; conversely, CYLD knockdown enhances this response (58). Similarly, USP38 negatively regulates IFN-I signaling by targeting the active form of TBK1 for degradation in vitro and in vivo (101). USP19 suppresses virus-induced IFN-I production by targeting TIR domain-containing adaptor inducing interferonb (TRIF, also known as Ticam1), which is an adaptor required for innate immune responses mediated by TLR3 and TLR4 (90). Together, these results indicate that the crosstalk between IFN-I and the Toll-like signaling pathway functions intricately in regulating host antiviral activities.
Altogether, the diversity of the mechanisms of DUB regulation enables the tight regulation of their function, which ensures an appropriate innate immune response against virus infections. To the best of our knowledge, at least twenty-four DUBs, A20, UCHL1, OTUB1, OTUB2, OTUD1, OTUD3, OTUD5, USP2B, USP3, USP5, USP7, USP13, USP14, USP15, USP18, USP19, USP21, USP22, USP25, USP27X, USP38, USP49, MYSM1, and MCPIP1, have so far been identified to negatively regulate virus-induced IFN-I production and antiviral activity. In contrast, DUBs, including CYLD, OTUD4, OTUD5, USP4, USP15, USP17, USP20, USP27X, USP29, and USP44, have been suggested to positively regulate host antiviral responses by targeting various substrates in this pathway ( Table 1). These DUBs mainly regulate the polyubiquitination levels of RIG-I, STING, MAVS, TRAFs, and TBK1, which function at different levels of this pathway ( Figure 3A), and this finding implies the physiological importance of these master proteins in innate immunity during viral infections. Of note, one DUB might target different proteins in the same pathway, whereas the same substrate might also be regulated by more than one DUB, which suggest the existence of dynamic and complex crosstalk between DUBs and substrates involved in IFN-I signaling-mediated antiviral activities. However, why so many DUBs are involved in host immune responses during viral infections remains unclear. One possible reason is that different DUBs may exert differential functions in response to various stimuli, and some of the Dubs might function redundantly in specific contexts. Second, the experimental tools and research biases might also contribute to the diverse roles of DUBs that have been identified. Moreover, some findings are only based on cell lines and overexpression systems and need to be confirmed in vivo and with genetic models in the future.

DUBS IN IFNAR-MEDIATED DOWNSTREAM SIGNALING AND THE ANTIVIRAL RESPONSE
In addition to their roles in virus-induced IFN-I production signaling, signaling molecules downstream of the IFN receptor play pivotal roles in affecting host antiviral efficiency. Because increasing the dosage of IFNs alone cannot significantly improve host antiviral efficiency, it has been proven that IFNs can induce ubiquitin-dependent degradation of the IFNAR receptor, which leads to a restriction effect on host antiviral activities (131,132). Consequently, it is similarly important to investigate the roles of DUBs involved in the IFNAR-mediated downstream signaling pathway. However, compared with the relatively large number of DUBs that regulate virus-induced IFN-I production ( Figure 3A), the number of DUBs that have been implicated in IFNARmediated downstream signaling has rarely been explored ( Figure 3B). In most cases, the regulatory effects of DUBs are mainly focused on the STAT1 protein, which functions as an essential transcription factor in IFNAR1-mediated downstream signaling. The ubiquitination and deubiquitination regulation events of STAT1 and its associated effects on the innate immune response have been increasingly investigated in recent years. For example, the three deubiquitinating enzymes BRCC36, USP13, and USP39 interact with STAT1 and decrease the K63-, K48-and K6-linked polyubiquitin chains of STAT1 respectively (110,115,118). These three DUBs positively regulate IFN-mediated antiviral activities and have been proposed to antagonize the degradation rate of STAT1 mediated by two E3 ligases, SLIM (133) and SMURF1 (134). More specifically, BRCC36 deficiency leads to a rapid downregulation of STAT1 during viral infection, whereas complementation by BRCC36 can rescue the STAT1 expression levels and suppress virus infection (110). BRCC36 sustains STAT1 protein turnover by recruiting USP13 to form a balanced complex to antagonize the SMURF1-mediated degradation of STAT1 (110). More specifically, USP13 positively regulates the antiviral activity of IFNa against DEN-2 virus replication by deubiquitinating and stabilizing STAT1 (115). Intriguingly, although USP39 was previously shown to not have deubiquitinase activity, recent studies have shown that USP39 combines with STAT1 and stabilizes its expression level by preventing the K6-linked polyubiquitination of STAT1 which promotes its degradation, and USP39 thus positively regulates IFN-I-mediated antiviral activities (118). Notably, IFN treatment could also promote USP2A to interact with pY701-STAT1 and maintain the pY701-STAT1 levels in the nucleus, which enhances IFN signaling-mediated antiviral activity (111). Unlike USP2A, the deubiquitinating enzymes BRCC36, USP13, and USP39 positively regulate IFN activities by attenuating the polyubiquitination level of STAT1, and this process is independent of IFN treatment, which suggests divergent functional roles of these DUBs under differential contexts.
Additionally, ATXN3 does not affect IFN-I production during viral infection but positively regulates IFNAR1-mediated downstream signaling by targeting HDAC3 (108). Another DUB, UCHL3, also positively regulates IFN-I-mediated antiviral activity by increasing the stability of COPS5 and IFNAR1 (121,122). Moreover, both USP7 and JOSD1 have been identified as negative regulators of IFNAR1-mediated downstream signaling by decreasing the polyubiquitin expression level of SOCS1 and thereby enhancing the turnover of SOCS1, which is a potent suppressor of IFN-I signaling (135). The IFN-inducible deubiquitinase USP18, which functions as one of the most important DUBs in IFN signaling, can downregulate type I IFN signaling by blocking the interaction between JAK1 and IFNAR2 (88,89,117). In addition, USP18 has enzymatic activity in cleaving the covalently conjugated 15-kDa protein encoded by interferon-stimulated gene 15 (ISG15) from its targeted substrates (136), and USP18 gene-knockout mice exhibit increased susceptibility to Salmonella typhimurium or Mycobacterium tuberculosis pathogen infections (137). Intriguingly, USP18 also acts as a negative regulator of microglia activation in mice. USP18 deficiency in microglial causes destructive interferonopathy in the mouse brain, suggesting that USP18 plays a protective role in microglia function by regulating the IFNAR pathway (138). Therefore, multiple DUBs are involved in regulating IFNARmediated downstream signaling during viral infection. However, whether other DUBs are similarly involved remains unknown, and the connection of DUBs with immune disorders and other related diseases still needs further research.

DUBS REGULATE IFN-I-MEDIATED ANTIVIRAL RESPONSES VIA THEIR PROTEASE ACTIVITY
Because DUBs are proteases, it is often speculated that the DUBs functioning in antiviral immunity are dependent on their deubiquitinating enzyme activities. The Ub chains of each substrate involved in IFN-I signaling are cleaved by various DUBs through either endo-or exo cleavage activity. Although the determination of whether a DUB cleaves with endo-or exocleavage activity seems difficult, several studies have shown that this activity relies on both the DUB structure and the type of Ub linkage (39). Indeed, the presence of seven internal lysine residues of the Ub (K6, K11, K27, K29, K33, K48, and K63) and the a-amino-terminus of methionine1 (Met1) enable the modification of target proteins with different types of polyubiquitin chains (conjugation of Ub molecules via the same lysine residue), heterotypic Ub chains (conjugation through different linkage patterns), branched chains, or monoubiquitination (38). Among the different types of polyubiquitin modifications, the principal and most abundant forms are K48-linked and K63-linked polyubiquitination. However, the outcomes of these different ubiquitination events for the substrate are distinct: K48-linked polyubiquitin chains are the best characterized and trigger substrates for proteasomal degradation more frequently than other modifications (139,140), whereas K63-linked chains play non degradative roles in cellular signaling, intracellular trafficking, the DNA damage response, and other contexts (141,142).
The K48-and K63-linked polyubiquitin modifications are also the most common types of PTMs identified in the proteins of the IFN-I signaling pathway ( Table 1). Although many Ub E3 ligases responsible for the K48-linked ubiquitination of proteins have been identified over the years (22,24,143), the corresponding DUBs in antagonizing the degradation and maintaining the protein stability of the key molecules in IFN signaling remain poorly understood (144). An overall view of the DUBs that specifically hydrolyze K48-linked polyubiquitin chains from various substrates during virus infections such as CYLD, OTUD4, OTUD5, USP1, USP4, USP14, USP15, USP20, USP25, USP27X, USP29, and USP44 is summarized in Table 1. These DUBs specifically hydrolyze K48-linked polyubiquitin chains from various substrates and thereby stabilize proteins and play positive roles during viral infection. More specifically, among the DUBs, CYLD deficiency promotes K48-linked polyubiquitination and degradation of STING and thereby decreases the induction of IRF3-responsive genes after HSV-1 infection. In accord with this observation, CYLD-knockout mice are more susceptible to HSV-1 infection than their wild-type littermates (59). The deubiquitinase OTUD4 interacts with MAVS to remove its K48-linked polyubiquitin chains and thereby maintains MAVS stability and promotes innate antiviral signaling. Additionally, the knockout of OTUD4 impairs RNA virus-triggered activation of IRF3 and NF-kB and the expression of their downstream target genes, and potentiates VSV replication in vitro and in vivo (66). Similarly, OTUD5 promotes the protein stability of STING via cleaving the K48-linked polyubiquitin chains. The knockout of OTUD5 leads to faster turnover of STING and impairs IFN-I signaling following cytosolic DNA stimulation, whereas Lyz2-Cre Otud5 fl/Y mice and CD11-Cre Otud5 fl/Y mice show higher susceptibility to HSV-1 infection than their corresponding control littermates (69). Among the USP members, USP1 functions as a viral infection-induced physiological enhancer of TBK1 expression when bound to USP1 the K48-linked polyubiquitination of TBK1, resulting in enhanced TLR3/4 and RIG-I-induced IRF3 activation and IFNb secretion (74). USP4, it positively regulates the RIG-I-mediated antiviral response by deubiquitinating K48-linked ubiquitin chains and stabilizing RIG-I (77). Interestingly, USP14, USP27X, and USP29 have been identified to positively regulate virus-induced IFN-I production by targeting the same substrate cGAS, and mechanistically, the three DUBs function by deubiquitinating K48-linked ubiquitin chains and stabilizing cGAS (83,98,99). Consistently, mice with the genetic ablation of USP27X and USP29 exhibit decreased levels of IFN-Is and proinflammatory cytokines after HSV-1 infection and hypersensitivity to HSV-1 infection compared with their wild-type littermates (98,99). In addition, although both USP20 and USP44 have been shown to positively regulate virus-induced IFN-I signaling by targeting the same substrate, STING, and removing its K48-linked polyubiquitin chains, these two DUBs function differently ( Table 1). Mechanistically, USP20 is recruited by USP18 to deconjugate K48-linked ubiquitination chains from STING and thus promotes the stability of STING and the expression of type I IFNs and proinflammatory cytokines after DNA virus infection (91). A later study, further confirmed that USP20 removes K48-linked ubiquitin chains from STING after HSV-1 infection and thereby stabilizes STING and promotes cellular antiviral responses (92). Congruently, USP20 knockout mice exhibit decreased levels of IFN-Is and proinflammatory cytokines, increased susceptibility to lethal HSV-1 infection, and aggravated HSV-1 replication compared with wild-type mice (92). The complementation of STING into Usp20 (-/-) cells remarkably restores HSV-1-triggered signaling and inhibits HSV-1 infection (92). In addition, the ectopic expression of USP15 enhances the TRIM25-and RIG-I-mediated production of type I IFN and thus suppresses RNA virus replication, whereas the depletion of USP15 causes decreased IFN production and markedly enhanced viral replication (85). Moreover, the DUB activity of USP25 is needed for virus-induced production of IFN-I and proinflammatory cytokines, because USP25 can stabilize TRAF3 by deubiquitinating K48-Ub on TRAF3 whereas the complemention of TRAF3/6 into USP25-deficient MEFs restores virus-induced signaling (96). Consistently, USP25-deficient mice are susceptible to H5N1 or HSV-1 infection than their wild-type counterparts (96).
Notably, although DUBs including OTUD1, USP5, and USP7 function to cleave K48-linked polyubiquitin chains of various substrates, the three DUBs exert opposite effects, which play negative roles in the host immune response against virus infection ( Table 1). For example, OTUD1 upregulates the protein levels of intracellular Smurf1 by removing the K48-linked polyubiquitin chains of Smurf1, and RNA virus infection promotes the binding of Smurf1 to MAVS, TRAF3, and TRAF6, which leads to ubiquitination-dependent degradation of the three proteins and subsequent potent inhibition of IFNs production (64). In agreement with this observation, OTUD1-deficient mice produce more antiviral cytokines and are more resistant to RNA virus infection (64). In addition, a recent systematic functional screening assay revealed that USP5 inhibits IFNb expression and promotes VSV replication by recruiting STIP1 homology and Ubox containing protein 1 (STUB1) to degrade RIG-I (40). Whereas USP7 acts as a negative regulator in antiviral signaling by stabilizing TRIM27 and promoting the degradation of TBK1, the knockout of endogenous USP7 leads to enhanced TRIM27 degradation and reduced TBK1 ubiquitination and degradation (79). In the case of IFNAR-mediated downstream signaling pathway, USP2A sustains interferon antiviral activity by restricting the K48-linked ubiquitination of p-STAT1 in the nucleus (111). Via using RNA interference screening strategy, USP13 was found to positively regulate IFN-I signaling by deubiquitinating the K48-linked polyubiquitin chains the of STAT1 protein (115). Congruently, STAT1 ubiquitination is reduced in cells by USP13 overexpression and increased with USP13 knockdown regardless of IFNa treatment (115). JOSD1 has been identified to negatively regulate IFN-I-induced signaling and the antiviral response by deubiquitinating the K48-linked polyubiquitination of SOCS1, which is an essential negative regulator of many cytokine signaling pathways (120).
K63-linked polyubiquitin modification, it has also been identified as fundamental for both the innate and adaptive immune systems. K63-linked polyubiquitin is not only needed for the virus-induced activation of TBK1 and IRF3 (145) but also widely involved in pathways including NF-kB signaling and MAPK activation (146,147). In NF-kB pathways, K63-linked polyubiquitin chains play pivotal roles in stabilizing the receptor signalosome on the membrane and hence facilitate the recruitment of adaptors or complexes and activating kinases (148). Critically, many E3 ligases, including TRAF6, are implicated in NF-kB pathways by catalyzing K63-linked polyubiquitination of various proteins (146). Whereas DUBs play an opposite role to E3 ligases, and various DUBs, including A20, CYLD, UCHL1, OTUD4, OTUD5, OTUD7B, USP18, USP25, and MYSM1, have been found to remove K63-linked polyubiquitin chains from various substrates (TBK1, TAK1, MyD88, TRAF3, and TRAF6) ( Table 1). Intriguingly, unlike the aforementioned DUBs, A20 is a hybrid of a DUB and a E3 ligase and has an N-terminal OTU domain responsible for polyubiquitin cleavage and C-terminal domaincontaining zinc fingers that bear E3 ligase activity. A20 cleaves the K63-linked polyubiquitin chains of TRAF6, RIP1, RIPK2, IKK-g, and MALT1 and hence suppresses NF-kB activation. Moreover, A20 has been shown to promote the K48-linked ubiquitination of RIP1, which leads to its degradation and thereby the downregulation of NF-kB signaling (146,149). Critically, K63linked ubiquitination also plays a pivotal role in affecting virusinduced IFN-I production by either stabilizing substrates or by acting as a scaffold for the formation of a signaling multi complex (150). To date, a panel of 15 DUBs, such as CYLD, UCHL1, OTUD1, OTUD3, OTUD4, OTUD5, USP2B, USP3, USP14, USP15, USP21, USP25, USP27X, USP49, and MYSM1, have been identified to cleave the K63-linked polyubiquitin chains on various proteins, which results in a positive or negative effect on virusinduced IFN-I production under different contexts ( Table 1). For example, OTUD3 removes K63-linked ubiquitin chains from MAVS and thereby inhibits MAVS aggregation and IFN-I signaling activation (65). In addition, unanchored K63 polyubiquitin chains can bind to MDA5, and this binding is important for signaling by MDA5, mutations of conserved residues in MDA5 disrupt its ubiquitin binding, and abrogate its ability to activate IRF3 (151). In the case of IFNAR1-mediated downstream signaling, BRCC36 sustains the protein turnover of IFNAR1 by removing K63-Ub from IFNAR1 (109), whereas USP5 has been identified to negatively regulate IFN-I-induced p-STAT1 activation and antiviral activities by removing K63-Ub on SMURF1 (112).
Additionally, some DUBs possess broad DUB activity against several types of Ub linkages. The DUBs OTUD7B, USP17, USP25, MCPIP1, ATXN3, and UCHL3 could simultaneously deconjugate the K48-and K63-linked Ub chains from the same protein in the IFN-I signaling pathway ( Table 1). For instance, ATXN3 sustains IFNAR1mediated downstream signaling by deubiquitinating both the K48-and K63-linked types of Ub chains on HDAC3 (108). However, USP13, USP19, and USP22 inhibit virus-induced IFN production by removing K27-linked polyubiquitin chains from STING (40,81) or TRIF (90). In contrast, USP38 combines with the active form of TBK1 via the NLR family pyrin domain containing 4 (NLRP4) signalosome and then cleaves K33-linked Ub chains from TBK1 at Lys670, which allows DTX4 and TRIP to catalyze K48-linked ubiquitination on the same residue (101). This process causes the degradation of TBK1, thus negatively regulates IFN-I signaling. Intriguingly, USP39 promotes IFN-mediated antiviral responses by decreasing K6-linked but not canonical K48-linked polyubiquitination of STAT1 for degradation (118), eventhough K6-linked ubiquitin chains are often related to DNA damage instead of protein degradation (142). Morever, although USP5 reportedly increases K11-and K48-linked ubiquitination of RIG-I upon virus infection and thereby facilitates the degradation of RIG-I (40), the detailed mechanism used by USP5 to enhance K11-linked Ub chains of RIG-I and the exact functions of K11-linked Ub chains implicated in the RIG-I-mediated signaling pathway remain elusive. Overall, the atypical K6-, K11-, K27-, K33-and linear-linked polyubiquitin chains of proteins also play critical roles in antiviral immunity and inflammation (152). However, little is known about K29-linked polyubiquitination, and whether this type of PTM occurs on substrates involved in IFN-I signaling remains unknown and warrants further research.

DUBS REGULATE HOST ANTIVIRAL ACTIVITY INDEPENDENTLY OF THEIR PROTEASE ACTIVITY
Although many studies have demonstrated that the protease activity of DUBs is critical in regulating the Ub chains on their substrates and affecting host IFN immune responses, some studies have also shown that the catalytic activity of certain DUBs is not necessary in regulating the IFN-I signaling pathway, which implies novel strategies used by DUBs. Mechanistically, the catalytically inactive mutant sites of DUBs could not abolish their negative or positive roles during virus infection, which indicates that these DUBs function independently of their protease activity. For instance, both the wild-type and enzymatically inactive mutant of USP5 can cause a decreased polyubiquitination level of SMURF1 (112), which suggest that USP5 functions in the immune response probably independently of its protease activity. In addition, some DUBs form complexes with adaptor or scaffold proteins, which act by recruiting proteins to participate in particular biological events, attracting trafficking factors that change substrate localization, or controlling substrate activity. For instance, DUBs can regulate a specific substrate by recruiting other factors, as demonstrated by USP10 recruits and binds with monocyte chemotactic protein induced protein 1 (MCPIP1) to deubiquitinate its substrate, nuclear factor kB essential modulator (NEMO) (153). Additionally, it has been shown that A20 blocks antiviral signaling by disrupting K63-linked polyubiquitination of TBK1-IKK complex independtly of the A20 deubiquitination domain (154). Futhermore, A20 prevents the interaction between Ubc13 and both TRAF2/5 and cIAP1/2 upon TNFa stimulation, which suggest A20 functions beyond its protease activity (155). In addition, A20 suppresses TNFa-induced NF-kB signaling through a noncatalytic mechanism that involves binding to polyubiquitin chains via its seventh zinc finger (ZnF7) (56,156,157). This binding is proposed to impede the recruitment of other linear polyubiquitin binding proteins that are essential for productive signaling downstream from TNFR (157). Moreover, USP5 suppresses IFNb expression and enhances VSV replication by recruiting STUB1 to degrade RIG-I (40). USP13, which shares ∼80% sequence similarity with USP5, negatively regulates virus-induced IFN-I production by inhibiting the recruitment of TBK1 to STING by deubiquitinating the K27-linked ubiquitin chains on STING (81), whereas USP22 recruits USP13 to cleave the K27-linked polyubiquitin chains from STING (40). USP18 does not deubiquitinate STING in vitro but facilitates USP20 to catalyze deubiquitination of STING in a manner independently of the enzymatic activity of USP18 (91). In addition, USP18-knockout mice are more susceptible to HSV-1 infection than their wild-type littermates, and the reintroduction of STING into USP18 −/− MEFs can restore the HSV-1-induced expression of downstream genes and cellular antiviral responses (91). In addition to being an active enzyme, USP18 can bind to the intracellular part of IFNAR2 and compete with the binding of JAK1 to the receptor, which results in negative regulation of IFNAR signaling independently of its protease activity (117). In the case of IFNAR-mediated downstream signaling, some other DUBs also implement their functions beyond their protease activities. For example, BRCC36 functions noncatalytically by recruiting USP13 to counteract the SMURF1-mediated degradation of STAT1, and this effect enhances the stability of STAT1 and improves host antiviral efficiency (110). Additionally, USP12 positively regulates IFN antiviral signaling independently of its deubiquitinase activity. Upon IFN treatment, USP12 accumulates in the nucleus, blocks the CREB-binding protein-induced acetylation of p-STAT1, and thus inhibits the dephosphorylation effects of TCPTP on p-STAT1, which ultimately maintains the nuclear p-STAT1 levels and IFN antiviral efficacy (114).
Because ubiquitination and related processes are involved in myriad aspects of human cell biology and physiology, abnormalities in such events can cause many diseases. Among these events, the dysregulation of DUB activity contributes to various sporadic and genetic diseases (158,164,165). For instance, human USP18 deficiency underlies type 1 interferonopathy, leading to severe pseudo-TORCH syndrome which is characterized by microcephaly, enlarged ventricles, cerebral calcification, and other severe complications (166). Similarly, the homozygous mutation of USP18 also causes severe type I interferonopathy because the mutated USP18 protein results in unmitigated interferonmediated inflammation and is lethal during the perinatal period (167). However, the treatment of these patients with ruxolitinib, a JAK 1/2 inhibitor, it significantly improves their symptoms (167). Additionally, a homozygous miss-sense mutation in STAT2 results in failure to appropriately traffic USP18 to IFNAR2 and prevents USP18 from negatively regulating responses to IFN-Is, which leads to infant death from autoinflammation disease (168). Notably, given that the current therapeutics remains incapable of achieving satisfying disease management in all patients, the therapeutic modulation of DUBs might be an attractive target in certain diseases. As has been demonstrated, although some inhibitors can treat cancer disease efficiently (169), the use of these inhibitors in the treatment of viral infectious diseases remains largely unexplored. Because DUB inhibition could promote steady-state Ub levels of specific substrates without affecting global protein or Ub levels, the development of small-molecule inhibitors targeted towards DUBs has increasingly become a promising strategy for drug discovery (170). However, because many DUBs are conserved during evolution and have a high sequence similarity, new perspectives are needed to facilitate the development of specific inhibitors. Consequently, the design of small-molecule inhibitors that interfere with the activity of DUBs or the DUB-substrate interactions accompanied by their relevance in vivo and related diseases remains one of the critical and challenging research areas.

CONCLUSIONS AND PERSPECTIVES
In summary, DUB-mediated regulation represents a crucial mechanism used by hosts to tightly regulate the extent of IFN signaling to achieve a balance between pathogen eradication and the prevention of excessive immune responses. However, how DUBs implement their diverse functions and interact with substrates in a dynamic, temporal, and spatial manner to ensure the most favourable outcome remains elusive. Intriguingly, some viruses also encode DUBs and other proteins that either act alone or interact with other cellular components to evade host immune surveillance (171,172). Thus, the interplay between DUBs and pathogens might add a new sophisticated mchanism that regulates the timing and amplitude of host immune responses to viral challenges. In addition, how PTMs (such as phosphorylation, acetylation, and methylation) of DUBs and, Ub and other unconventional Ub structures modulate the functional shift of DUBs and thus affect host innate immune signaling, is still poorly understood. Future studies exploring the detailed mechanisms of DUBs, their inducers, and downstream targets during viral infections might help improve the present understanding of the mechanisms of host innate immune responses, and these findings could lead to the identification of novel targets and help guide the development of therapeutic strategies for the treatment of human diseases.

AUTHOR CONTRIBUTIONS
The table and graphs were prepared by LZ. The literature was collected and analyzed by GL and YL. JP and ZZ provided insightful comments and suggestions on the manuscript. GQ and HL wrote the paper and critically revised the draft. All authors contributed to the article and approved the submitted version.